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S294 Poster Session IIBackground:The outcomes of patients infected with respiratory vi-
ruses prior to allogeneic hematopoietic cell transplantation (HCT)
are largely unknown. We sought to determine whether respiratory
virus detection before HCT influenced overall survival, days hospi-
talized, and incidence of bronchoscopy during the first 100 days after
HCT.
Methods: Pre-HCT and weekly post-HCT nasal washes were col-
lected from patients through day 100 between 12/2005 and 04/
2010. Nasal and bronchoalveolar lavage samples, if available, were
tested by PCR for respiratory syncytial virus (RSV), parainfluenza vi-
rus (PIV) types 1-4, influenza A&B (Flu), metapneumovirus (MPV),
adenovirus (AdV), rhinoviruses (RHV), coronaviruses (CoV), and
bocavirus (BoV). We analyzed outcomes between patients with
and without pre-transplant infections. We defined viruses associated
with less severe respiratory disease (RHV, CoV, BoV) as Group 1,
and those with more severe disease (RSV, PIV, Flu, MPV, AdV) as
Group 2. Hospitalization was analyzed as number of days alive and
not hospitalized.
Results:Respiratory viruses were detected in samples between 1 and
60 days (median 17 days) before HCT from 115 (25%) of 453 pa-
tients. Those with a respiratory virus detected were younger (p 5
0.002) and more likely to have high-risk underlying disease (p 5
0.009). In a multivariable model, patients with positive pre-HCT
samples had significantly worse survival and averaged nearly 10 fewer
days out of the hospital between day 1 and 100 (Table). Group 2 vi-
ruses were associated with increased incidence of undergoing bron-
choscopy.
Conclusion: One in 4 patients was infected with a respiratory virus
before HCT. The presence of a pre-HCT respiratory virus infection
was associated with increased mortality, prolonged hospitalization,
and increased pulmonary morbidity. Unfortunately, delay of HCT
is often not feasible and effective treatment is unavailable for most
respiratory viruses. These data emphasize the need for intensified
prevention of pre-HCT respiratory virus acquisition and improved
management strategies, including the development of new antiviral
agents.388
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(alloHSCT) IS UNDERUTILIZED IN MYELODYSPLASTIC SYNDROME
(MDS): A POPULATION-BASED CANADIAN PROVINCE EXPERIENCE
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Introduction: A recent decision withholding approval for HSCT
for Medicare beneficiaries with MDS prompted this study to inves-
tigate the utilization of allogeneic transplant in young patients (pts)
presenting withMDS. InManitoba (population 1.2 million) HSCTs
are performed in one center and there is no funding restriction for
eligible pts with MDS. There is a robust provincial cancer registry.
Methods: (1) We retrospectively studied a cohort of pts with MDS
in Manitoba to determine the number who underwent alloHSCT
compared to potentially eligible cases. Transplant eligibility was de-
fined as: (a) age # 65yr and (b) IPSS Int-2 and high risk groups, or
poor prognostic features such as: refractory cytopenias, blasts $
10%, high risk cytogenetics, therapy-related MDS and RCMD
with cytopenias (BBMT 2009; 15: 137-72 and BMT 2009; 43: 597-
609). (2) The Manitoba BMT (MBMT) registry was searched to de-
termine the number of alloHSCTs forMDS and other disorders per-
formed from 1991 to 2008.
Results: (1) In the two year period of 2006-2007 there were 80 inci-
dent cases of MDS or CMML (excluding RAEB-t) (Kumar et al Blood
2009; 114: Abstract#245). Of these, 23 pts (29%) were# 65 yrs of age;
9 of themwere considered ineligible for HSCT (6 - no poor prognos-
tic features, 2 - associated malignancy, 1- incomplete data). In the re-
maining 14 (18%), only 4 pts underwent alloHSCT and of these, 2
were transplanted after transformation and therapy for AML. The
median overall survival was 7 months (95% CI 3.6-12.2) for the 10
pts who were not transplanted (Table). AlloHSCT for MDS priorto leukemic transformation was done in only 14% (2/14) of eligible
pts. (2) The MBMT registry data over 18 yrs showed that 20 pts re-
ceived an alloHSCT for MDS or CMML, including 8 with RAEB-
t. As 18 of these 20 pts were residents of Manitoba, a mean of one al-
loHSCT for MDS per year was performed for the province. During
the same period, 277 alloHSCTswere carried out.MDS cases formed
7% of all alloHSCTs performed inManitoba, and 40%of theseMDS
pts had RAEB-t, now classified as AML.
Conclusion:Within the limitations of retrospective analysis, we es-
timate that only 18% of MDS patients were eligible for alloHSCT.
Moreover, alloHSCT has been under-utilized, as only 14% of these
eligible pts actually received alloHSCT prior to disease progression.
Earlier referrals to the BMT program may increase the number of
HSCTs. These observations may be useful in the planning of health
services for MDS.
Table 1. Prognostic Features of 10 transplant eligible patients
of MDS treated withoutHSCT:median age 62 yr (range 46-65)
No of Pts Prognostic features5 IPSS- Int-2 or High Risk
1 IPSS 0.5: Therapy related RCMD and Hb <80g/L
4 IPSS not known in 4: Blasts >10% -1; high risk
cytogenetics -1; Platelets 39 x109 -1; RCMD
and ANC 0.6 x109 -1.389
THROMBOTIC MICROANGIOPATHY WITH TACROLIMUS/SIROLIMUS-
BASED GVHD PROPHYLAXIS REGIMEN IN PATIENTS UNDERGOING HE-
MATOPOIETIC STEM CELL TRANSPLANT
Shayani, S.1, Palmer, J.2, Stiller, T.2, Rodriguez, R.3, Khuu, T.1,
Parker, P.M.4, Snyder, D.S.4, Pullarkat, V.4, Rosenthal, J.4,
Nademanee, A.4, Senitzer, D.4, Forman, S.J.4, Khaled, S.5,
Nakamura, R.4 1City of Hope National Medical Center, Duarte, CA;
2City of Hope National Medical Center, Duarte, CA; 3Kaiser Perma-
nente, Los Angeles, CA; 4City of Hope National Medical Center, Duarte,
CA; 5City of Hope National Medical Center, Duarte, CA
Thrombotic microangiopathy (TMA) is a multifactorial compli-
cation of allogeneic hematopoietic stem cell transplant (HCT).
The true incidence of TMA is difficult to estimate due to lack of
agreement on a single definition. Diagnosis is often complicated
by multiple potential etiologies for the clinical findings. Recently,
the addition of sirolimus (SIR) to tacrolimus (TAC) was reported
to result in a higher than expected incidence of TMA (Cutler et al.
BBMT 2005). We evaluated the incidence and risk factors for
TMA in patients who received allo-HCT using SIR/TAC-based
GVHD prophylaxis at City of Hope. TMA was defined as SCr in-
crease of $ 50% above baseline, LDH . 2x upper normal limit,
presence of schistocytes or persistent presence of nucleated RBCs,
and prolonged or progressive thrombocytopenia (\ 50 x 109/L or
$ 50% decrease). A case series of 183 patients who underwent sib-
ling donor (n 5 85) or MUD HCT (n 5 98) were included in this
study. The median age was 46 years (range: 10-70); Conditioning
regimens consisted of Flu/Mel (60%), FTBI/Cy or FTBI/VP16
(32%) and Bu/Cy (8%). Thirty-one (17%) patients met the above di-
agnostic criteria for TMAwithin the first 100 days post-HCT. In ad-
dition, we included 9 patients who did not meet the criteria due to
a missing test but were clinically diagnosed with TMA by indepen-
dent attending physicians, resulting in the total incidence of 22%
(40/183). Seven of the 40 patientsmet the criteria forTMA as a result
of ongoing multi-organ failure. The median time to TMA onset was
4.7 weeks (range: 1.6-12.6). Thirty-four patients developed both
TMA and aGVHD, in which the majority of patients (85%) devel-
oped TMA after a diagnosis of aGVHDhad beenmade. Themedian
of the median TAC and SIR levels over the first 30 days post HCT
were 8.9ng/ml (IQR: 7.7-10.2) and 6.5ng/ml (IQR: 5.2-8.6). Bymul-
tivariable analysis, we identified the following factors to be associated
with increased risk of TMA: 1) highest quartile of serum sirolimus
exposure: level $ 8.6 (HR: 2.52, 95%CI:0.99-6.39, p 5 0.05), 2)
aGVHD grades II-IV (HR: 3.43, 95%CI: 1.67-7.05, p\ 0.01), 3)
low-risk disease (HR: 1.92, 95%CI: 1.00-3.69, p5 0.05), and 4) fully
ablative conditioning (HR: 2.24, 95%CI: 1.16-4.34, p 5 0.02). In
Poster Session II S295conclusion, TMA is common after allo-HSCTusing SIR-containing
GVHD prophylaxis. The risk factors for TMA suggest that careful
monitoring and adjustment of TAC/SIR dosages to avoid super-
therapeutic levels is critical, particularly during ongoing GVHD.390
A NOVEL NON MYELOABLATIVE REGIMEN FOR RELATED AND UNRE-
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Allogeneic transplant can cure chronic granulomatous disease and
is increasingly being offered. However, presence of persistent unre-
sponsive severe infection deters transplant of this high-risk group,
though nonmyeloablative regimens with matched sibling donors
can succeed. In 2007 we initiated a protocol for this high-risk group
using either matched sibling or unrelated donors and show that a tol-
erance-based regimen allows for engraftment with little to no infec-
tion progression or GVHD. Using low dose Busulfan, Campath and
Rapamycin with TBI for unrelated donor recipients, we have now
transplanted 11 patients (ages 3-32); 9 with an unrelated 10/10
HLAmatched donor or a 5/6 cord blood, and 2 with a sibling donor.
We have had one primary graft failure with autologous recovery oc-
curring in the cord blood recipient who had significantly lower bu-
sulfan levels as compared to the other patients. The others all
engrafted (neutrophil count$ 500 for 3 days) by day 65 (averageday
26), showingz100% donor chimerism in the CD14/15 lineages as
measured by STR PCR. CD3 engraftment was slower with many
having less than 10%donor chimerism initially. The average number
of RBC transfusions was 2.4 units/patient with 4 patients requiring
none and 4 also not needing platelet transfusions. GVHD has been
limited to 1 patient with Grade II and 1 with Grade I of the skin.
Overall survival is 10 of 11 with 1 patient dying from non-transplant
related causes. Our longest follow up to date is 2 years in a patient
with continued full engraftment and normal immunologic function.
2 patients required a stem cell boost given without additional condi-
tioning, either for slow engraftment or unstable chimerism, and
a third patient appears to have late graft rejection with studies ongo-
ing. Most significantly, 9 of 11 patients were transplanted at the time
of an ongoing fungal or bacterial infection of lung, spine, and/or me-
ninges, often resistant to multidrug therapies. 4 patients were given
granulocyte infusions during their neutropenia. No patient had evi-
dence of infection progression, and a number showed radiologic im-
provement prior to full engraftment. Thus we have developed
a regimen with minimal GVHD, even with unrelated donors and/
or ongoing infection. Longer follow up and more patients will
help confirm our enthusiasm for this approach to treating these
high risk patients not otherwise eligible for transplant.391
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EBV remains important pathogen in patients after haematopoietic
stem cell transplantation (HSCT). Beside benign reactivation, EBV
can cause localised or generalised form of EBV associated lympho-
proliferative disease (EBV-LPD) with clinical symptoms such asfever, hepathopathy, lymphoma-like symptoms and generalised B
cell proliferation in peripheral blood.
Between I/2002 and X/2010, we tested prospectively whole blood
samples from 266 children (8,202 samples) and from 489 adults
(7,202 samples) after allogeneic HSCT. A minute number of addi-
tional tissue and body fluids samples was tested too. Retrospectively,
we tested 50 samples from 4 children who died for EBV-LPD in
2000. EBV and albumin gene were quantified using RQ-PCR and
quantity of EBV was normalised to 100,000 human genome equiva-
lents and expressed in normalised viral copies (NVCs).
In the prospective testing, EBV was detected in whole blood of
199 children (74.8%;2607 samples;median 90 normalised viral cop-
ies (NVCs) and from 301 adults (62.7%;1,749 samples;median 79
NVCs). More than 1 000 copies were detected in 62 children and
57 adults,more than 10,000 in 14 children and 13 adults. Clinical
or laboratory signs of EBV-LPD were observed in 8 children and
12 adults. Generalised EBV-LPD confirmed by detection of abnor-
mal B lymphocytes in peripheral blood was detected in 6 children
and 4 adults (mean of highest EBV 103,566 NVCs), localised form
in 2 child and 7 adults (mean of highest EBV 10,652NVCs). Despite
the rituximab treatment 3 prospectively tested adults deceased due to
treatment resistant EBV-LPD. Among retrospectively tested pa-
tients, highest quantity was between 1,165,000-11,060,500 NVCs
and the interval between the first detection of EBV and decease
was 24-91 days.
EBV can be detected in big proportion of patients after HSCT,
more frequently in paediatric population. Level of 10,000 NVCs
seems to be a good level for possible treatment and it is 100 times le-
ver than highest quantity detected patients who died of EBV-LPD.
Long lasting EBV positivity in patient with lymphomas suppose to
be EBV released from the local proliferation. Normalisation proved
to be useful approach for comparison of EBV levels in the whole
blood and in the tissues.Supported by MSMT 0021620813 and
MZ0FNM2005.392
IMPACT OF THE DISTRIBUTION AND THE EFFECT OF KIRS AND ACTIVAT-
ING KIR ON OUTCOME OF HLA-IDENTICAL SIBLING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Wei, X., Feng, Y., Sun, A., Wu, D., Tang, X. Jiangsu Institute of Hema-
tology, Suzhou, Jiangsu, China
Objective:To investigate the distribution and the effect of killer cell
immunoglobulin-like receptor (KIR) genes, as well as to explore the
impact of different activating KIRs in HLA-identical sibling hema-
topoietic stem cell transplantation (HSCT).
Methods: The genotypes of donor/recipient KIR were determined
by polymerase chain reaction-sequence specific primer (PCR-SSP)
in 40 cases of HLA-identical sibling HSCT. And a retrospective
study was carried out to analyze the outcomes of the recipients.
Results: All the patients and the donors possessed KIR
2DL1,2DL2,2DL3,3DL2,3DL3, and 95% of individuals possessed
3DL1. The frequencies of KIR2DS4, KIR2DS1, KIR3DS1,
KIR2DS5, KIR2DS2 and KIR2DS3 were 95%, 40%, 36.25%,
31.25%, 21.25%, and 20% respectively in 40 pairs of donor-recipi-
ent. The frequencies of KIR2DS4*001/002 and 2DS4*003-007 ho-
mozygotes were 55.9% and 8.8% respectively, while the frequency
for 2DS4*001/002 and 2DS4*003-007 heterozygote was 35.3%.
Among them, 62.5% of donor/recipient KIR were completely iden-
tical, while 37.5% were not. Of the non-identical KIRs,12.5% were
the recipients KIR genotype containing the donors ones,5% were
the donors KIR containing the recipients KIR, and 20% were com-
pletely different. The donor/recipient KIR completely identical
group had higher aGVHD rate and the higher incidence of III-
IVaGVHD compared with KIR not identical group (64%
vs.26.7%, P\ 0.05 and 28% vs. 0%, P\ 0.05 respectively). The
KIR not identical group had higher 2-year disease-free survival
(DFS) compared with KIR completely identical group
[(91.6767.98)% vs. (77.7869.81)%,P 5 0.3]. The incidence of re-
lapse was 19.2% when the donor without KIR2DS2, but was 0%
for the donor with KIR2DS2. Among the A/A donors, the disease-
free survival (DFS) of one year was 70% when the donor had
2DS4*003-007,and 87.5% when the donor was KIR2DS4*001/002
